Lassen Therapeutics Commences Dosing in Phase 1 Clinical Study of LASN01, a First-in-Class Interleukin-11 Receptor-Blocking Antibody October 3, 2022
DEM BioPharma Establishes Leadership Team with Appointment of Nenad Grmusa as CEO and Christophe Quéva, Ph.D., as CSO September 27, 2022
Immunitas Therapeutics Receives FDA Clearance of IND Application for IMT-009 in Solid Tumors and Hematological Malignancies September 23, 2022
Photys Therapeutics Debuts with $75 Million Series A Funding to Advance New Class of Bifunctional Molecules for Precision Phosphorylation to Modulate and Repair Disease-Driving Proteins September 8, 2022
Werewolf Therapeutics Announces Initiation of Patient Dosing in Phase 1/1b Clinical Trial of WTX-124 for the Treatment of Patients with Selected Solid Tumors September 2, 2022
